MOPEAD Publications

August 23, 2020

Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain

J Clin Med . 2020 Aug 24;9(9):E2726. doi: 10.3390/jcm9092726.

Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital.

July 23, 2020

A European multinational project to develop and test innovative patient engagement strategies

July 24, 2018: Alzheimer's Association International Conference: P3‐01: Poster Presentations

December 01, 2019

Patient engagement strategies to move towards earlier diagnosis of Alzheimer’s disease

Eurohealth — Vol.25, No.4, 2019

Alzheimer’s disease (AD) is an incurable disease that steals memories, identities, livelihoods and lives. We now know more about the pathophysiology of the disease and the scope of various preventative mechanisms; we also know that early intervention and treatment in AD can be both beneficial and cost-effective. Despite the importance of a timely diagnosis, many patients are not diagnosed at all. A cultural shift towards making the diagnosis of AD at a very early stage needs to be encouraged. The early recognition of AD is the first step towards providing patients with optimal opportunities for intervention.

July 17, 2019

AAIC 2019

This poster was presented at the AAIC 2019 in Los Angeles by Cambridge Cognition (or CANTAB). It outlines interim analysis of the Alzheimer's disease citizen science platform developed by the MOPEAD Project (or Run 1). This patient engagement model invited members of the general public in five European countries to take an online memory test with the possibility of receiving further health assessment or even a diagnosis in exchange for their data to be used as part of the study. 

May 13, 2019

Alzheimer's & Dementia, The Journal of the Alzheimer's Association

In most, if not all health systems, dementia is underdiagnosed, and when diagnosis occurs, it is typically at a relatively late stage in the disease process despite mounting evidence showing that a timely diagnosis would result in numerous benefits for patients, families, and society. Moving toward earlier diagnoses in Alzheimer's disease (AD) requires a conscientious and collective effort to implement a global strategy addressing the multiple causes hindering patient engagement at different levels of society. This article describes the design of the Models of Patient Engagement for Alzheimer's Disease project, an ongoing EU-funded public-private multinational initiative that will compare four innovative patient engagement strategies across five European countries regarding their ability to identify individuals with prodromal AD and mild AD dementia, which are “hidden” in their communities and traditionally not found in the typical memory clinic setting. The strategies include an online AD citizen science platform, an open house initiative at the memory clinics, and patient engagement at primary care and diabetologist clinics.

September 30, 2018

Dementia in Europe: The Alzheimer Europe Magazine

A special 16-page supplement showcasing the work of the MOPEAD was published alongside the Alzheimer Europe 2018 Dementia in Europe magazine. The supplement includes a general overview of the project, information about each of the project's work-streams and their goals, as well as interviews with the project leadership.

March 13, 2018

Patient Engagement: The Fundacio ACE ´ Framework for Improving Recruitment and Retention in Alzheimer’s Disease Research

Journal of Alzheimer’s Disease 62 (2018) 1079–1090 DOI 10.3233/JAD-170866

Alzheimer’s disease (AD) research is at a critical time. The global society is increasingly aware of the frightening rate of growth of the human and financial burden caused by this condition and of the urgent need to halt its progression. Consequently, the scientific community holds great responsibility to quickly put in place and optimize the machinery necessary for testing new treatments or interventions. In this context demand for participants for AD research is at an all-time high. In this review, we will focus on a methodological factor that is increasingly recognized as a key factor that shapes trial populations and affects validity of results in clinical trials: patient engagement, recruitment, and retentionTo address the urgent need for more research studying the applicability and cost effectiveness of different recruitment strategies across different settings and nationalities, we describe the Models of Patient Engagement for Alzheimer’s Disease (MOPEAD) project, a public-private partnership promoted by the Innovative Medicine Initiative (IMI), which will provide a large multinational quantitative analysis comparing different innovative recruitment models.

Please reload